Using advanced computational simulations, researchers at the University of Chicago have revealed just how remdesivir works at the molecular level, and also found that two drugs that work in a similar manner, ribavirin and favilavir, do not bind as effectively to the virus.Read more
Researchers from the National University of Singapore have utilised a ground-breaking AI platform to find an optimal combination of available therapies against COVID-19. The research team identified the drug combination from over 530,000 possibilities within two weeks, cutting down the number of tests typically needed by hundreds of thousands.Read more
COVID-19 and Monoclonal Antibodies – Emergency Use Authorization for Bamlanivimab The FDA’s Emergency Use Authorization to treat high risk COVID-19Read more
In a review of evidence from the most reliable data from randomized trials to find likely small-to-moderate effects of remdesivir, researchers say that totality of evidence compiled before the WHO trial results justifies compassionate use of remdesivir for severely ill patients. A smaller trial in China showed significantly decreased mean recovery time but no suggestion of a mortality benefit. ACTT-1 found the same mean recovery time and a suggestion of a mortality benefit that did not achieve statistical significance.Read more
J. Randall Curtis, MD, MPH is Chair in Pulmonary and Critical Care Medicine, Department of Medicine | UW Medicine; past-president of the American ThoracicRead more
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA—Sofosbuvir/Velpatasvir—in combination with other drugs in COVID-19 clinical trials.Read more
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.Read more
A new analysis by University of Chicago Medicine faculty, staff and collaborators around the world found remdesivir appears to be equally beneficial to patients regardless of race, supporting the need for early intervention and aggressive care for all patients in the fight against COVID-19.Read more
A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.Read more
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Penn State Health Milton S. Hershey Medical Center has enrolled its first patients in the continuation of a clinical trial using the investigational antiviral drug remdesivir for treatment of COVID-19.Read more
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.Read more